Tags

Type your tag names separated by a space and hit enter

A copper-lowering strategy attenuates amyloid pathology in a transgenic mouse model of Alzheimer's disease.
J Alzheimers Dis 2010; 21(3):903-14JA

Abstract

There is increasing evidence for the crucial role of metals in the pathology of Alzheimer's disease. Both the aggregation and neurotoxicity of amyloid-β are dependent on the presence of copper. This study investigated the ability of the copper-complexing drug tetrathiomolybdate to reduce amyloid-β pathology and spatial memory impairment in both a prevention and a treatment paradigm in the Tg2576 mouse model of Alzheimer's disease. Tetrathiomolybdate treatment lowered brain copper and reduced amyloid-β levels in the prevention paradigm, but not in the treatment paradigm. Our data suggests that controlled lowering of systemic copper may achieve anti-amyloid effects if initiated early in the disease process.

Authors+Show Affiliations

Portland Veterans Affairs Medical Center, P3 R&D, Portland, OR, USA. quinnj@ohsu.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.

Language

eng

PubMed ID

20693639

Citation

Quinn, Joseph F., et al. "A Copper-lowering Strategy Attenuates Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease." Journal of Alzheimer's Disease : JAD, vol. 21, no. 3, 2010, pp. 903-14.
Quinn JF, Harris CJ, Cobb KE, et al. A copper-lowering strategy attenuates amyloid pathology in a transgenic mouse model of Alzheimer's disease. J Alzheimers Dis. 2010;21(3):903-14.
Quinn, J. F., Harris, C. J., Cobb, K. E., Domes, C., Ralle, M., Brewer, G., & Wadsworth, T. L. (2010). A copper-lowering strategy attenuates amyloid pathology in a transgenic mouse model of Alzheimer's disease. Journal of Alzheimer's Disease : JAD, 21(3), pp. 903-14. doi:10.3233/JAD-2010-100408.
Quinn JF, et al. A Copper-lowering Strategy Attenuates Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease. J Alzheimers Dis. 2010;21(3):903-14. PubMed PMID: 20693639.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A copper-lowering strategy attenuates amyloid pathology in a transgenic mouse model of Alzheimer's disease. AU - Quinn,Joseph F, AU - Harris,Christopher J, AU - Cobb,Katherine E, AU - Domes,Christopher, AU - Ralle,Martina, AU - Brewer,George, AU - Wadsworth,Teri L, PY - 2010/8/10/entrez PY - 2010/8/10/pubmed PY - 2011/1/19/medline SP - 903 EP - 14 JF - Journal of Alzheimer's disease : JAD JO - J. Alzheimers Dis. VL - 21 IS - 3 N2 - There is increasing evidence for the crucial role of metals in the pathology of Alzheimer's disease. Both the aggregation and neurotoxicity of amyloid-β are dependent on the presence of copper. This study investigated the ability of the copper-complexing drug tetrathiomolybdate to reduce amyloid-β pathology and spatial memory impairment in both a prevention and a treatment paradigm in the Tg2576 mouse model of Alzheimer's disease. Tetrathiomolybdate treatment lowered brain copper and reduced amyloid-β levels in the prevention paradigm, but not in the treatment paradigm. Our data suggests that controlled lowering of systemic copper may achieve anti-amyloid effects if initiated early in the disease process. SN - 1875-8908 UR - https://www.unboundmedicine.com/medline/citation/20693639/A_copper_lowering_strategy_attenuates_amyloid_pathology_in_a_transgenic_mouse_model_of_Alzheimer's_disease_ L2 - https://content.iospress.com/openurl?genre=article&id=doi:10.3233/JAD-2010-100408 DB - PRIME DP - Unbound Medicine ER -